Arch Biopartners publishes data linking IL-32 to inflammation and diabetic kidney disease

Arch Biopartners announced that its scientists published data linking the cytokine IL-32 to inflammation and diabetic kidney disease, and the release notes ongoing development of drug candidates targeting chronic kidney disease and the DPEP-1 pathway.

Arch Biopartners issued a press release reporting that its scientists published data linking the cytokine IL-32 to inflammation and diabetic kidney disease. The release highlights the company’s ongoing work on drug candidates for chronic kidney disease and the DPEP-1 pathway. It also includes forward-looking language about clinical trials involving LSALT peptide (Metablok) and cilastatin. Known details: - The company published data associating IL-32 with inflammation and diabetic kidney disease. - The press release notes ongoing development of drug candidates targeting chronic kidney disease and the DPEP-1 pathway. - The release includes forward-looking statements about clinical trials (LSALT peptide/Metablok and cilastatin), potential regulatory approvals, and business risks. - A company contact link is provided for trial updates and company news. Summary: Arch Biopartners reports the publication linking IL-32 to inflammation and diabetic kidney disease and states it is continuing development of related drug candidates. No specific trial outcomes, regulatory decisions, or timelines are provided. Undetermined at this time.